# Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

> **NCT01694485** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 359 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** Abrilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01694485
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-16
- **Primary completion:** 2015-07-13
- **Final completion:** 2018-04-10
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01694485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01694485, "Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01694485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*